SEC Form 4 · accession 0001209191-15-086952
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane Wasman
Officer — President, Intl and GC
Period of report
Dec 22, 2015
Accepted (ET)
Dec 24, 2015 · 8:04 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 22, 2015 | M | 5,342 | $5.85 | A | 113,921 | D | |
| Common StockF1 | Dec 22, 2015 | S | 5,342 | $43.00 | D | 108,579 | D | |
| Common StockF2,F3 | Dec 22, 2015 | S | 8,455 | $42.0729 | D | 100,124 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F4 | $5.85 | Dec 22, 2015 | M | 5,342 | D | — | Mar 17, 2016 | Common Stock | 5,342 | 10,751 | D |
Explanation of responses
- F1Exercises and sales pursuant to a 10b5-1 Plan. The exercised options were scheduled to expire in 2016 on the expiration date reported within Table II unless exercised.
- F2Sales pursuant to a 10b5-1 plan.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $42.00 to $42.30 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The shares subject to these options vested in installments and were fully vested on February 10, 2010.